Emergent facility to work on TB, typhoid vaccines

Emergent BioSolutions plans to renovate a 55,000-square-foot facility. The facility isn't slated to open until 2012; however, upon its completion, the expansion will not only give Emergent more space to fill government contracts for BioThrax, but also will allow the developer to start testing commercial vaccines for ailments like tuberculosis and typhoid. Report

Editor's Note: Article modified to remove "in Baltimore" from first sentence.

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.